Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: Results of a phase II dose-finding study

Medicine and Dentistry

• Adverse Event 18%
• Amaurosis 9%
• Beta1a Interferon 100%
• Crohn's Disease 36%
• Cytokine 9%
• Degeneration 9%
• Experience 9%
• Flu Like Syndrome 9%
• Group Therapy 9%
• Headache 9%
• Injection Site Reaction 9%
• Inpatient 18%
• Interim Analysis 9%
• Interleukin 12 9%
• Multiple Sclerosis 36%
• Patient 72%
• Patient with Crohn's Disease 18%
• Spontaneous Remission 18%
• Steroid 18%
• Therapeutic Procedure 18%
• Thinking 9%

INIS

• cytokines 9%
• diseases 54%
• doses 27%
• influenza 9%
• injection 9%
• interferon 100%
• interleukins 9%
• maintenance 9%
• patients 100%
• safety 18%
• steroids 18%
• symptoms 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 18%
• Beta1a Interferon 100%
• Blindness 9%
• Crohn Disease 36%
• Cytokine 9%
• Flu Like Syndrome 9%
• Headache 9%
• Injection Site Reaction 9%
• Interleukin 12 9%
• Multiple Sclerosis 36%
• Placebo 90%
• Remission 18%
• Steroids 18%